Waiting and “weighted down”: the challenge of anticipatory loss for individuals and families with Li-Fraumeni Syndrome

被引:0
作者
Allison Werner-Lin
Jennifer L. Young
Catherine Wilsnack
Shana L. Merrill
Victoria Groner
Mark H. Greene
Payal P. Khincha
机构
[1] University of Pennsylvania,School of Social Policy and Practice
[2] Stanford Center for Biomedical Ethics,Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics
[3] National Cancer Institute,Center for Genetic Medicine
[4] Hospital of the University of Pennsylvania,undefined
[5] Feinberg School of Medicine,undefined
来源
Familial Cancer | 2020年 / 19卷
关键词
Li-fraumeni syndrome; Hereditary cancer; Family; Bereavement; Family therapy; Anticipatory loss;
D O I
暂无
中图分类号
学科分类号
摘要
Li-Fraumeni Syndrome (LFS) is characterized by risk of multiple primary malignancies in diverse sites, pediatric onset, near complete penetrance by age 70 years, limited options for prevention, and substantial uncertainty regarding disease manifestation and prognosis. Forty-five families, including 117 individuals aged 13–81 years, enrolled in the US National Cancer Institute’s Li-Fraumeni Syndrome Study completed 66 interviews regarding their LFS experiences. An interdisciplinary team used modified grounded theory to examine family distress regarding expectations of loss and change due to likely cancer diagnoses, and the consequences of this likelihood across physical, social, and emotional domains. Disease-free periods were characterized by fearful anticipation of diagnosis or recurrence, uncertainty regarding post-treatment quality of life, and planning for shifts in family dynamics to enable caregiving. The chronicity of waiting for these changes incited dread and inhibited effective coping with the pragmatic, emotional, and existential challenges of the syndrome. Consequently, families reported high burden on roles and resources and limited guidance to prepare for, or achieve resolution with, grief. Anticipatory loss, the experience of bereavement prior to an expected change, distinguishes hereditary cancer risk from a sporadic diagnosis. Such grief is often incomplete in impact or meaning, subjected to rapid or profound change as conditions worsen, and poorly understood. In this study, losses were compounded by profound uncertainty, a chronic feature of LFS, which compromised mourning. Long-term engagement of mental health providers with bereavement training, in partnership with genetics providers, can provide invaluable educational and psychological support to families as they navigate these implacable challenges.
引用
收藏
页码:259 / 268
页数:9
相关论文
共 50 条
  • [41] Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
    Birch, JM
    Blair, V
    Kelsey, AM
    Evans, DG
    Harris, M
    Tricker, KJ
    Varley, JM
    ONCOGENE, 1998, 17 (09) : 1061 - 1068
  • [42] Novel p53 splice site mutations in three families with Li-Fraumeni syndrome
    Verselis, SJ
    Rheinwald, JG
    Fraumeni, JF
    Li, FP
    ONCOGENE, 2000, 19 (37) : 4230 - 4235
  • [43] Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence
    Young, Jennifer L.
    Pantaleao, Ashley
    Zaspel, Lori
    Bayer, Jessica
    Peters, June A.
    Khincha, Payal P.
    Bremer, Renee C.
    Loud, Jennifer T.
    Greene, Mark H.
    Achatz, Maria Isabel
    Savage, Sharon A.
    Werner-Lin, Allison
    JOURNAL OF PSYCHOSOCIAL ONCOLOGY, 2019, 37 (02) : 178 - 193
  • [44] Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts
    Burt, E. C.
    James, L. A.
    Greaves, M. J.
    Birch, J. M.
    Boyle, J. M.
    Varley, J. M.
    BRITISH JOURNAL OF CANCER, 2000, 83 (04) : 467 - 472
  • [45] Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation
    Ferreira, Amanda Meneses
    Brondani, Vania Balderrama
    Helena, Vanessa Petry
    Silva Charchar, Helaine Laiz
    Nogueira Zerbini, Maria Claudia
    Senna Leite, Luiz Antonio
    Hoff, Ana Oliveira
    Latronico, Ana Claudia
    Mendonca, Berenice Bilharinho
    Estevez Diz, Maria Del Pilar
    de Almeida, Madson Queiroz
    Barisson Villares Fragoso, Maria Candida
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2019, 190 : 250 - 255
  • [46] Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts
    E C Burt
    L A James
    M J Greaves
    J M Birch
    J M Boyle
    J M Varley
    British Journal of Cancer, 2000, 83 : 467 - 472
  • [47] Pilot study of the prevalence of autoimmune disorders in Li-Fraumeni syndrome
    Obregon, Ixtaccihuatl H.
    de Andrade, Kelvin C.
    Bremer, Renee C.
    Khincha, Payal P.
    Savage, Sharon A.
    FAMILIAL CANCER, 2023, 22 (03) : 319 - 321
  • [48] Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1
    Kumamoto, Tadashi
    Yamazaki, Fumito
    Nakano, Yoshiko
    Tamura, Chieko
    Tashiro, Shimon
    Hattori, Hiroyoshi
    Nakagawara, Akira
    Tsunematsu, Yukiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2161 - 2178
  • [49] EGFR-mutated lung cancer in Li-Fraumeni syndrome
    Michalarea, Vasiliki
    Calcasola, Matthew
    Cane, Paul
    Tobal, Khalid
    Izatt, Louise
    Spicer, James
    LUNG CANCER, 2014, 85 (03) : 485 - 487
  • [50] Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy
    Spees, Colleen K.
    Kelleher, Kelly J.
    Abaza, Ronney
    Clinton, Steven K.
    UROLOGY CASE REPORTS, 2015, 3 (02) : 21 - 23